tradingkey.logo
tradingkey.logo
Search

Integra Lifesciences Holdings Corp

IART
Add to Watchlist
16.650USD
-0.470-2.75%
Close 07-31 16:00ETQuotes delayed by 15 min
1.29BMarket Cap
LossP/E TTM

TradingKey Stock Score of Integra Lifesciences Holdings Corp

Currency: USD Updated: 2026-07-31

Key Insights

Integra Lifesciences Holdings Corp's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 65 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 20.00.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Integra Lifesciences Holdings Corp's Score

Industry at a Glance

Industry Ranking
65 / 199
Overall Ranking
139 / 4281
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Integra Lifesciences Holdings Corp Highlights

StrengthsRisks
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Undervalued
The company’s latest PE is -2.58, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 82.80M shares, decreasing 14.91% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 2.53K shares of this stock.

Analyst Rating

Based on 12 analysts
Hold
Current Rating
20.000
Target Price
+20.12%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Integra Lifesciences Holdings Corp?

The TradingKey Stock Score provides a comprehensive assessment of Integra Lifesciences Holdings Corp based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Integra Lifesciences Holdings Corp’s performance and outlook.

How do we generate the financial health score of Integra Lifesciences Holdings Corp?

To generate the financial health score of Integra Lifesciences Holdings Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Integra Lifesciences Holdings Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Integra Lifesciences Holdings Corp.

How do we generate the company valuation score of Integra Lifesciences Holdings Corp?

To generate the company valuation score of Integra Lifesciences Holdings Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Integra Lifesciences Holdings Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Integra Lifesciences Holdings Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Integra Lifesciences Holdings Corp.

How do we generate the earnings forecast score of Integra Lifesciences Holdings Corp?

To calculate the earnings forecast score of Integra Lifesciences Holdings Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Integra Lifesciences Holdings Corp’s future.

How do we generate the price momentum score of Integra Lifesciences Holdings Corp?

When generating the price momentum score for Integra Lifesciences Holdings Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Integra Lifesciences Holdings Corp’s prices. A higher score indicates a more stable short-term price trend for Integra Lifesciences Holdings Corp.

How do we generate the institutional confidence score of Integra Lifesciences Holdings Corp?

To generate the institutional confidence score of Integra Lifesciences Holdings Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Integra Lifesciences Holdings Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Integra Lifesciences Holdings Corp.

How do we generate the risk management score of Integra Lifesciences Holdings Corp?

To assess the risk management score of Integra Lifesciences Holdings Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Integra Lifesciences Holdings Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Integra Lifesciences Holdings Corp.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.